Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
Provider: Wright Reports
Provider: Reuters Investment Profile
Provider: Thomson Reuters StreetEvents

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Otsuka Holdings Co Ltd Announces Approval for Abilify Maintena of Subsidiary and H Lundbeck A/S in Europe

Thursday, 21 Nov 2013 02:00am EST 

Otsuka Holdings Co Ltd announced that its subsidiary Otsuka Pharmaceutical Co., Ltd. and H Lundbeck A/S announced marketing authorization approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole. Abilify Maintena reduces the risk of relapse relative to placebo over the long-term and provides treatment of schizophrenia. 

Company Quote

4.6 +3.58%
10:59am EST